Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neptune blasts off with Bayer

This article was originally published in The Tan Sheet

Executive Summary

The Canadian maker of omega-3 phospholipid ingredients announces Bayer Healthcare will commercialize its proprietary products in the U.S. Neptune Technologies & Bioresources credits its "complete portfolio of scientific data, intellectual property and regulatory approvals" with paving the way for the partnership. The firm said June 4 it expects Bayer will help broaden consumer awareness of its products, including Neptune Krill Oil and Advantage NKO dietary supplement. Neptune's strategy is "to penetrate world nutraceutical and pharmaceutical markets" through collaborations with global partners, said Henri Harland, president and CEO for the Laval, Quebec-based company. Neptune previously teamed with Yoplait on functional yogurts and shifted the license for its cardiovascular application portfolio to subsidiary Acasti Pharma (1"The Tan Sheet" Sept. 1, 2008, In Brief)

You may also be interested in...

Neptune shifts operations

Neptune Technologies & Bioresources transfers the license for its cardiovascular application portfolio to operating subsidiary Acasti Pharma to develop active pharmaceutical ingredients for products in the Rx, OTC and medical food markets, the firm announces Aug. 21. Under the arrangement, Quebec-based Acasti will research, develop and market the APIs, with the goal of entering strategic pharmaceutical partnerships. Neptune announced a deal with Yoplait in June 2007 to provide its Neptune Krill Oil - a composition with proprietary omega-3 phospholipids - for use in functional yogurt products (1"The Tan Sheet" July 2, 2007, In Brief)

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Sales Already Growing As Vascepa Secures Cardio Approval





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts